At its Capital Markets Day on September 21, Novo Nordisk announced ambitious plans to launch more than five multi-blockbuster drugs by 2030 and achieve over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar emphasized prioritizing asset quality over deal size, focusing on bolt-on acquisitions but remaining open to larger deals. In Q2, sales of the weight-loss drug Wegovy rose 42.6% quarter-on-quarter to about DKK 3.2 billion, while rare endocrine disorder treatments generated DKK 1.54 billion, up 8.3% year-on-year and 34.1% quarter-on-quarter. These developments highlight Novo Nordisk's strong growth trajectory and strategic focus on high-quality assets.
Novo Nordisk's market cap stands at $170.60 billion as of September 24, 2026, with a dividend yield of 4.71%, reflecting its strong position in the health sector. On Pluang, the stock price is $38.59, up 1.10% on the day, supported by high investor interest with 89% of orders being buys. These figures highlight sustained confidence in Novo Nordisk's growth strategy following its recent Capital Markets Day announcements.
Novo Nordisk's CEO Mike Doustdar said the Danish pharma company is open to a direct listing on the New York Stock Exchange, which would replace its current American depositary receipt (ADR) structure. However, the company is not actively pursuing thi...
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Novo Nordisk held its investor day in London, outlining its strategy for growth after its key obesity drugs lose patent protection. Despite plans for multiple new blockbusters and expansion into heart and liver disease treatments, analysts were unimp...
Novo Nordisk CEO Mike Doustdar revealed the company is actively considering mergers and acquisitions to strengthen its position in the competitive weight-loss drug market. He emphasized the company's interest in acquiring or partnering with firms tha...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
